Drugs that contain Leuprolide Acetate
1. Eligard Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8470359 | TOLMAR THERAP | Sustained release polymer |
Oct, 2023
(a month ago) | |
Market Authorisation Date: 13 February, 2003
Treatment: Method of treating cancer
Dosage: POWDER;SUBCUTANEOUS
ELIGARD KIT family patents
2. Eligard Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11771841 | TOLMAR | Systems and methods for mixing syringe valve assemblies |
Dec, 2041
(18 years from now) | |
Market Authorisation Date: 23 January, 2002
Treatment: NA
Dosage: POWDER;SUBCUTANEOUS
ELIGARD KIT family patents
3. Fensolvi Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8470359 | TOLMAR | Sustained release polymer |
Oct, 2023
(a month ago) | |
| US11771841 | TOLMAR | Systems and methods for mixing syringe valve assemblies |
Dec, 2041
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | May 1, 2023 |
Market Authorisation Date: 01 May, 2020
Treatment: Method of treating pediatric patients 2 years of age and older with central precocious puberty
Dosage: POWDER;SUBCUTANEOUS
FENSOLVI KIT family patents
4. Lupron Depot patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815801 | ABBVIE ENDOCRINE INC | Controlled release composition and method of producing the same |
Jun, 2022
(1 year, 5 months ago) | |
| US8921326 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Feb, 2031
(7 years from now) | |
Market Authorisation Date: 22 December, 1995
Treatment: Palliative treatment of prostate cancer
Dosage: INJECTABLE;INJECTION
LUPRON DEPOT family patents
5. Lupron Depot-ped Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9617303 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Mar, 2028
(4 years from now) | |
| US8921326 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Feb, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength (NS) | Apr 14, 2026 |
Market Authorisation Date: 16 April, 1993
Treatment: Treatment of pediatric patients with central precocious puberty
Dosage: POWDER;INTRAMUSCULAR
LUPRON DEPOT-PED KIT family patents